intratumoral EGFR antisense DNA
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for intratumoral EGFR antisense DNA, covering 2022-09-21 to 2022-09-21. Get the full timeline:
Most recent: Clinical Trial Update: Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma [Phase 1, Phase 2]